- Home
- BNY vs FENC Comparison
BNY vs FENC Comparison
Compare BNY & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- FENC
- Stock Information
- Founded
- BNY 2001
- FENC 1996
- Country
- BNY United States
- FENC United States
- Employees
- BNY N/A
- FENC N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BNY Finance
- FENC Health Care
- Exchange
- BNY Nasdaq
- FENC Nasdaq
- Market Cap
- BNY 230.8M
- FENC 225.4M
- IPO Year
- BNY N/A
- FENC 2001
- Fundamental
- Price
- BNY $10.17
- FENC $8.67
- Analyst Decision
- BNY
- FENC Strong Buy
- Analyst Count
- BNY 0
- FENC 2
- Target Price
- BNY N/A
- FENC $13.50
- AVG Volume (30 Days)
- BNY 52.7K
- FENC 56.7K
- Earning Date
- BNY 01-01-0001
- FENC 11-06-2025
- Dividend Yield
- BNY 3.93%
- FENC N/A
- EPS Growth
- BNY N/A
- FENC N/A
- EPS
- BNY N/A
- FENC N/A
- Revenue
- BNY N/A
- FENC $33,302,000.00
- Revenue This Year
- BNY N/A
- FENC $0.18
- Revenue Next Year
- BNY N/A
- FENC $52.59
- P/E Ratio
- BNY N/A
- FENC N/A
- Revenue Growth
- BNY N/A
- FENC N/A
- 52 Week Low
- BNY $8.60
- FENC $3.96
- 52 Week High
- BNY $10.80
- FENC $9.42
- Technical
- Relative Strength Index (RSI)
- BNY 82.67
- FENC 48.25
- Support Level
- BNY $9.39
- FENC $8.42
- Resistance Level
- BNY $10.24
- FENC $9.11
- Average True Range (ATR)
- BNY 0.09
- FENC 0.32
- MACD
- BNY 0.05
- FENC -0.04
- Stochastic Oscillator
- BNY 89.86
- FENC 29.14
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.